AOD-9604 has a genuinely unusual history for a peptide that's still widely sold: it went through real human trials, and the company running them walked away from it. That's a more informative fact than most of the marketing around it mentions.
What AOD-9604 is
AOD-9604 is a synthetic fragment of human growth hormone, covering amino acids 176 to 191, the region researchers believed was responsible for HGH's fat-metabolizing effects without the growth-promoting or blood-sugar effects of full HGH. It was developed by the Australian company Metabolic Pharmaceuticals as a potential obesity drug.
What's actually been studied
- Early-phase safety trials. Several Phase I/II trials, covering several hundred participants combined, reported an acceptable safety profile.
- The pivotal Phase 2b obesity trial. Metabolic Pharmaceuticals ran a large, randomized obesity trial (internally called the OPTIONS study) that fully enrolled in 2006. Interim reporting during the trial described a modest average weight-loss difference favoring the treated group over 12 weeks (BioSpace, trial progress coverage; News-Medical, early trial reporting).
- The actual result. When the full 24-week Phase 2b data was analyzed, the trial did not demonstrate weight-loss efficacy against placebo. Metabolic Pharmaceuticals did not advance AOD-9604 to Phase 3 trials, and as far as I could find, the pivotal trial's full results were never published in a peer-reviewed journal, only reported through company disclosures and trade press (diabetesincontrol.com, contemporaneous coverage).
Where the evidence is thin
This is about as clear an example of "the trial didn't work" as exists in this category. Early interim data looked promising enough to generate trade-press headlines, and the final, fully-powered result didn't hold up. Compounding that, I could not locate the pivotal trial's complete results in a peer-reviewed, PubMed-indexed publication, meaning the most important dataset on this compound's actual efficacy was never put through standard peer review for public scrutiny. Preclinical, animal-model evidence for fat-related effects exists, but the one large human efficacy trial that was run came back negative.
The regulatory picture
AOD-9604 is not FDA-approved for any use. Its drug development program was discontinued in 2007 after the Phase 2b result. It's sold by research chemical vendors strictly for laboratory research, not for human use.
Papa's take
I find AOD-9604's story more useful as a cautionary example than as a compound to get excited about. A real company ran a real, adequately sized trial, and it didn't show the effect they were testing for. That's exactly the kind of result that should carry weight in how this compound gets discussed, and in my read of the online conversation around it, it mostly doesn't.
Sources
- Metabolic Pharmaceuticals's Obesity Trial Update, BioSpace
- Obesity drug codenamed AOD9604 highly successful in trials, News-Medical, 2004
- Successful Trial for Phase 2B Fat Burner, diabetesincontrol.com
Sourcing for research
If you're sourcing AOD-9604 for laboratory research, purity documentation matters. See my vendor comparisons for how I evaluate third-party certificates of analysis.